1.32
Phio Pharmaceuticals Corp (PHIO) 最新ニュース
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 - TMX Newsfile
PHIO: RNA immunotherapy shows strong tumor clearance and safety, advancing to next clinical phase - TradingView — Track All Markets
Phio Pharmaceuticals to Discuss 'Nobel Prize Winning Science' for Skin Cancer Treatment - National Today
EPS Watch: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Trade Ideas & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - TMX Newsfile
Phio spotlights skin cancer candidate after 65% response rate - Stock Titan
Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation - Stock Titan
Ideas Watch: Does Phio Pharmaceuticals Corp have declining or rising EPSNew Guidance & Risk Controlled Swing Alerts - baoquankhu1.vn
Phio Pharmaceuticals Corp. Enters Material Definitive Agreement – SEC 8-K Filing Details April 8, 2026 - Minichart
Phio Pharmaceuticals Establishes New At-the-Market Equity Program - TipRanks
Phio Pharmaceuticals CorpEnters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026 - TradingView — Track All Markets
Phio Pharmaceuticals (NASDAQ: PHIO) launches $6.36M at-the-market stock plan - Stock Titan
Phio Pharmaceuticals (PHIO) files $6.36M ATM with H.C. Wainwright - Stock Titan
Pyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology - EIN News
What dividend growth rate does Phio Pharmaceuticals Corp offer2026 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Profit Review: Is Phio Pharmaceuticals Corp on track to beat earningsSwing Trade & Detailed Earnings Play Alerts - baoquankhu1.vn
VIX Spike: Is Phio Pharmaceuticals Corp being accumulated by smart moneyQuarterly Risk Review & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - The National Law Review
Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply - The Globe and Mail
Phio Pharmaceuticals Signs U.S. cGMP Manufacturing Agreement for PH-762 Drug Product Clinical Supply - Minichart
Phio Pharmaceuticals secures U.S. cGMP manufacturer for PH-762 clinical and commercial supply - TradingView — Track All Markets
Phio (NASDAQ: PHIO) inks PH-762 manufacturing deal after strong 65% response - Stock Titan
Phio lines up U.S. supply for skin cancer drug as PH-762 trials advance - Stock Titan
Dow Update: Can Phio Pharmaceuticals Corp lead its sector in growth - baoquankhu1.vn
Phio Pharmaceuticals Corp (44R1.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phio Pharmaceuticals Corp (44R1.MU) stock price, news, quote and history - Yahoo Finance UK
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals to present PH-762 cancer trial data Friday By Investing.com - Investing.com South Africa
Phio Pharmaceuticals to present PH-762 cancer trial data Friday - Investing.com
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - marketscreener.com
A skin cancer study with 65% response sends Phio to a late-breaker stage - Stock Titan
Cancer biotech Phio Pharmaceuticals stock surges as trial shows tumor clearance at highest dose in skin cancer patients - MSN
Aug Macro: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Historical Comparison & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Retail Trends: Is Phio Pharmaceuticals Corp being accumulated by smart money2026 Performance Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office - Bitget
Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan
Sidoti Boosts Earnings Estimates for Phio Pharmaceuticals - Defense World
PHIO: RNA therapy for skin cancer shows 85% response and no toxicities, advancing to pivotal trials - TradingView
Phio Pharmaceuticals Corp. Financial Disclosures & SEC Filings - TradingView
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT - GlobeNewswire
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT - TMX Newsfile
Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan
How Phio Pharmaceuticals Corp. stock compares to industry benchmarksBuy Signal & High Accuracy Trade Signal Alerts - Naître et grandir
EV Market: Is Phio Pharmaceuticals Corp being accumulated by smart moneyJuly 2025 Sector Moves & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - marketscreener.com
Cancer drug PH-762 completes safety phase as Phio raises $23.7M - Stock Titan
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - marketscreener.com
Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan
PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm
大文字化:
|
ボリューム (24 時間):